Drug Profile
Anti-infective skin replacement therapy - Stratatech
Alternative Names: ExpressGraft™ - Anti-microbial; ExpressGraft™ - C9T1; NIKSC9T1Latest Information Update: 28 Mar 2021
Price :
$50
*
At a glance
- Originator Wisconsin Alumni Research Foundation
- Developer National Institute of Diabetes and Digestive and Kidney Diseases; Stratatech
- Class Cell therapies
- Mechanism of Action Cathecilidin expression stimulants; Tissue replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Diabetic foot ulcer; Varicose ulcer
Most Recent Events
- 28 Mar 2021 No recent reports of development identified for phase-I development in Diabetic-foot-ulcer(In the elderly, In adults) in USA (Topical, Patch)
- 14 Jan 2021 Stratatech terminates a phase I trial for Diabetic foot ulcer (In adults, In the elderly) in USA due to business decision not related to product quality or safety concerns (NCT04134143)
- 07 Nov 2019 Stratatech initiates enrolment in a phase I trial for Diabetic foot ulcer (In adults, In the elderly) in USA (NCT04134143)